阿巴西普在风湿病患者中HBsAg逆转血清学风险仅次于利妥昔单抗
该回顾性队列研究纳入489例接受bDMARDs治疗且乙肝已缓解的类风湿关节炎患者,随访67 828人月,27例(5.5%)发生HBsAg逆转血清学。多因素分析显示利妥昔单抗、阿巴西普及基线抗-HBs阴性为独立危险因素,阿巴西普在抗-HBs低滴度或阴性患者中HBsAg逆转血清学累积发生率达35.4%-62.5%。
要点
- 利妥昔单抗和阿巴西普是HBsAg逆转血清学的独立危险因素。
- 基线抗-HBs阴性者HBsAg逆转风险升高(调整HR 5.15)。
- 抗-HBs阳性但水平不足者仍不能免除HBV再激活风险。
核心结论
- 阿巴西普与利妥昔单抗均使乙肝已缓解的类风湿关节炎患者面临较高的HBV再激活风险。
- 抗-HBs阳性若水平不够高,不能保证接受利妥昔单抗或阿巴西普治疗者不发生HBV再激活。
研究设计与样本
- 2003至2019年回顾性纳入1937例有HBsAg和抗-HBc数据的类风湿关节炎患者,其中489例乙肝已缓解且接受bDMARDs治疗。
- 随访67 828人月,分析HBsAg逆转血清学相关因素。
主要发现
- 27例(5.5%)患者在bDMARD治疗后发生HBsAg逆转血清学。
- 发生HBsAg逆转者较未发生者年龄更大、抗-HBs阳性频率更低、基线抗-HBs水平更低。
- 多因素分析中利妥昔单抗调整HR 87.76(95%CI 11.50-669.73,p<0.001)。
- 阿巴西普调整HR 60.57(95%CI 6.99-525.15,p<0.001)。
- 基线抗-HBs阴性调整HR 5.15(95%CI 2.21-12.02,p<0.001)。
关键数值与推荐
- HBsAg逆转血清学风险与抗-HBs水平呈负相关。
- 利妥昔单抗和阿巴西普均可能导致抗-HBs丢失。
- 阿巴西普在抗-HBs低滴度或阴性患者中HBsAg逆转血清学累积发生率为35.4%-62.5%。
临床怎么用
- 对乙肝已缓解的类风湿关节炎患者使用利妥昔单抗或阿巴西普前应评估抗-HBs水平。
- 抗-HBs水平不足者即使阳性也需警惕HBV再激活,应加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B surface antigen (HBsAg) reverse seroconversion (RS) can happen in patients with rheumatoid arthritis (RA) with resolved hepatitis B (RHB) undergoing biological disease-modifying antirheumatic drugs (bDMARDs). But the incidence and risk factors need to be delineated. METHODS: From 2003 to 2019, 1937 patients with RA with available HBsAg and antibody to hepatitis B virus (HBV) core antigen data were retrospectively reviewed, and 489 patients with RHB undergoing bDMARDs treatment were identified. Factors associated with HBsAg RS were analysed. RESULTS: During 67 828 person-months of follow-up, 27 (5.5%) patients developed HBsAg RS after bDMARD treatment. As compared with those without HBsAg RS, patients with HBsAg RS were older, had lower frequency of antibody to HBsAg (anti-HBs), and lower baseline anti-HBs levels. In multivariate analysis, rituximab, abatacept and baseline negative for anti-HBs were the independent risk factors for HBsAg RS (adjusted HR: 87.76, 95% CI: 11.50 to 669.73, p<0.001; adjusted HR: 60.57, 95% CI: 6.99 to 525.15, p<0.001; adjusted HR: 5.15, 95% CI: 2.21 to 12.02, p<0.001, respectively). The risk of HBsAg RS was inversely related to the level of anti-HBs. Both rituximab and abatacept might result in anti-HBs loss, and abatacept had a cumulative incidence of HBsAg RS of 35.4%-62.5% in patients with low titers or negative of anti-HBs. CONCLUSIONS: Not only rituximab, but also abatacept has a high risk of HBV reactivation in patient with RA with RHB. Anti-HBs positivity cannot confer HBV reactivation-free status if the anti-HBs levels are not high enough for patients with RHB on rituximab and abatacept treatment.
引用
- Chen MH, Lee IC, Chen MH, et al. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Ann Rheum Dis. 2021. PMID: 34187776. doi:10.1136/annrheumdis-2021-220774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。